GT Biopharma
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
EBITDA | -3,411 | -3,710 | 825 | -2,962 |
EBIT | -3,604 | -3,906 | -2,266 | -6,130 |
Net Income | -3,411 | -3,710 | -2,266 | -2,962 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -2,737 | -3,536 | -4,163 | -2,047 |
Cash | 6,418 | 9,249 | 1,950 | 1,079 |
Basic Shares | 2,234 | 1,711 | 1,380 | 1,380 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
EBITDA | 5,979 | -20,965 | -57,477 | -24,976 |
EBIT | -7,597 | -42,222 | -114,992 | -24,980 |
Net Income | -7,597 | -20,503 | -58,693 | -31,616 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Cost of Revenue | 5,269 | |||
Free Cash Flow | -8,852 | -15,217 | -15,606 | -7,262 |
Cash | 1,079 | 5,672 | 8,968 | 5,297 |
Basic Shares | 1,347 | 1,062 | 938 | 146 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$1.52 |
2024-06-30 | -$2.16 |
2024-03-31 | -$1.64 |
2023-12-31 | -$2.19 |
